A retrospective review of 1300 cataract operations by one surgeon finds office-based surgeries are no less safe than ...

In a conversation with HT Lifestyle, Dr Rishi Raj Borah, Country Director at Orbis, highlighted one of the most common and ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...

Dublin, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The "Corneal Edema - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. A comprehensive report has been released ...

and efficacy of AURN001 for the treatment of corneal edema secondary to corneal endothelial dysfunction. Ninety-seven subjects were randomized at US and Canadian sites to each of the following ...

Corneal edema, also called corneal swelling, is a buildup of fluid in your cornea, the clear lens that helps focus light onto the back of your eye. One common cause of corneal edema is a problem ...

EO2002 was studied in EMME-001 as a treatment for corneal edema without the need for invasive and high-risk surgical procedures, such as corneal transplantation or endothelial scraping.

The CLARA clinical trial is a prospective, multi-center, randomized, double-masked, parallel-arm cell dose-ranging study in subjects with corneal edema secondary to corneal endothelial dysfunction.

EO2002 offers the promise of a treatment for corneal edema without the need for invasive and high-risk surgical procedures such as corneal transplantation. Currently, approximately 10% of patients ...

The corneal edema market is projected to witness consistent growth throughout the forecast period (2023–2034). The market size of corneal edema in the US is expected to increase, driven by the ...